Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.
Humacyte’s fair value estimate has been reset from US$7.86 to US$2.05, marking a sharp recalibration of how analysts are framing the stock’s potential. Recent research highlights a split view, with some analysts leaning into the acellular vessel opportunity after the V012 data and others trimming expectations, which together help explain the lower fair value target. As you read on, you will see what is driving this evolving Humacyte narrative and how to keep track of the next key inflection points.
Stay updated as the Fair Value for Humacyte shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Humacyte.
What Wall Street Has Been Saying 🐂 Bullish Takeaways
Several firms point to Humacyte’s V012 interim data as a key support for the story, with TD Cowen and H.C. Wainwright highlighting that the study met its primary endpoint and showed positive secondary analyses.
H.C. Wainwright lifted its price target to US$4 from US$3 after the V012 update, citing expectations around a dialysis indication and a view that the acellular vessel platform can support future revenue over time.
Benchmark raised its target to US$2 from US$1 after discussions with management, reflecting updated assumptions for Symvess and the acellular tissue engineered vessel AV graft in its model.
TD Cowen previously raised its target to US$1.50 from US$1, pointing to Symvess and potential indication expansion in AV access, CABG and PAD, which it sees as larger market opportunities.
🐻 Bearish Takeaways
More recently, TD Cowen reduced its target to US$1.25 from US$1.50, despite a positive view on the V012 data, suggesting increased caution on execution, timelines or valuation assumptions around Humacyte.
Mentions of lower targets and a downgrade at firms like Barclays, Piper Sandler and Benchmark signal that some analysts are more guarded on risk, even as they continue to track the same clinical and regulatory milestones.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!
NasdaqGS:HUMA 1-Year Stock Price Chart
We’ve flagged 3 risks for Humacyte. See which could impact your investment.
How This Changes the Fair Value For Humacyte
Fair value reset from US$7.86 to US$2.05, reflecting materially revised assumptions for Humacyte’s outlook.
Long term revenue growth assumption moved from 463% to 313%.
Long term net profit margin outlook reduced from 36.85% to 0.34%.
Future P/E multiple assumption changed from 21.60x to 1,434.48x.
Discount rate adjusted from 7.43% to 8.01%.
Story Continues
Never Miss an Update: Follow The Narrative
Narratives connect Humacyte’s clinical story and commercial roll out to a structured financial forecast and fair value range. They update automatically as new trial data, regulatory milestones and capital raises come through, so you can see how the story is evolving in real time.
Head over to the Simply Wall St Community and follow the Narrative on Humacyte to stay up to date on:
How Symvess use in trauma and hospital acquired vascular complications, plus ECAT and VA access, could shape surgeon adoption and institutional demand.
What the V012 dialysis trial and potential label expansion around 2027 might mean for recurring procedure volumes and the broader acellular vessel platform.
Key execution risks, including pricing pressure, early stage commercialization, cash burn, and uncertainty around longer dated CABG and tubular organ programs.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include HUMA.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com